{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-25-000446","form_type":"8-K","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.911563+00:00","generated_at":"2026-05-24T06:48:19.786442+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"confidence":"high","headline":"TOI Q4 2024 revenue up 16.9% to $100M; net loss narrows to $13.2M; 2025 guidance revenue $420-450M","bullets":["Revenue $100M (+16.9% YoY); net loss $13.2M vs $18.8M; EPS -$0.14 vs -$0.21.","Positive Q4 operating cash flow of $4.2M; SG&A down 12% YoY.","Added six new value-based contracts in H2 2024 covering over 250k lives; dispensary revenue at record.","2025 guidance: revenue $420-$450M, adjusted EBITDA loss $19-$24M, improved free cash flow.","New drug-supplier agreement expected to improve discounts and cost positioning."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-25-000446","json":"https://secwatch.observer/filing/0001079973-25-000446.json","markdown":"https://secwatch.observer/filing/0001079973-25-000446.md","text":"https://secwatch.observer/filing/0001079973-25-000446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325000446/0001079973-25-000446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325000446/toi_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:48:19.786442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}